Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Eisai GmbH, Lyoner Straße 36, 60528 Frankfurt am Main, Germany, e-mail: medinfo_de@eisai.net
Targretin 75 mg soft capsules.
| Pharmaceutical Form |
|---|
|
Soft capsule. Off-white capsule, containing a liquid suspension and imprinted with “Targretin”. |
Each capsule contains 75 mg of bexarotene.
Excipient(s) with known effect: sorbitol
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bexarotene |
Bexarotene is a synthetic compound that exerts its biological action through selective binding and activation of the three RXRs: α, β, and γ. Once activated, these receptors function as transcription factors that regulate processes such as cellular differentiation and proliferation, apoptosis, and insulin sensitisation. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown. |
| List of Excipients |
|---|
|
Capsule content: Macrogol Capsule shell: Gelatin |
High-density polyethylene bottles with child-resistant closures containing 100 capsules.
Eisai GmbH, Lyoner Straße 36, 60528 Frankfurt am Main, Germany, e-mail: medinfo_de@eisai.net
EU/1/01/178/001
Date of first authorisation: 29 March 2001
Date of latest renewal: 24 April 2006
| Drug | Countries | |
|---|---|---|
| TARGRETIN | Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
